1Mousa SA. Antiplatelet therapies: from aspirin to GP Ⅱ b/Ⅲ a-receptor antagonists and beyond[J].Drug Discov Today,1999,4(12):522-561
2Ashby B, Daniel JT, Smith JB. Mechanisms of platelet activation and inhibition[J].Hematol Oncol Clin North Am,1990,4(1):1-26
3Hacke W, Brott T, C.apJan L, et al.Thrombolysis in acute ischemic stroke:controlled trials and clinical experience[J].Neurology,1999,53(7 Suppl 4):S3-S14
4Busch E, Kruger K, AUegrini PR, et al. Reperfusion after thrombolytic therapy of embolic stroke in the rat:magnetic resonance and biochemical imaging[J].J Cereb Blood Folw Metab,1998,18(4):407-418
5Tcheng JE.Clinical challenges of platelet glycoprotein Ⅱb/Ⅲ a receptor inhibitor therapy:bleeding,reversal,thrombocytopenia,and retreatment[J].Am Heart J,2000,139(2 Pt 2):S38-S45
6Junghans U,Seitz RJ,Aulich A,et al.Bleeding risk of tirofiban,a nonpeptide GPⅡb/Ⅲ a platelet receptor antagonist in progressive stroke:an open pilot study[J].Cerebrovase Dis,2001,12(4):308-312
7Vivekananthan DP, Patel VB, Moliterno DJ.Glycoprotein Ⅱb/Ⅲa antagonism and fibrinolytic therapy for acute myocardial infarction[J].J Interv Cardiol,2002,15(2):131-139
8Haas TA,Plow EF.The cytoplasmic domain of αⅡ bβ3.A ternary complex of the integrin α and β subunits and a divalent cation[J].J Biol Chem,1996,27(11):6017-6026
9Dickfeld T,Ruf A,Pogatsa-Murray G,et al.Differential antiplatelet effects of various glycoperotein Ⅱb／Ⅲa antagonists[J].Thromb Res,2001,101(2):53-64
10Honda S,Tomiyama Y,Aok T,et al.Association between ligand-induced conformational changes of integrin Ⅱbβ3 and Ⅱhβ3-mediated intracellular Ca^2+ signaling[J].Blood,1998,92(10):3675-3683
